Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Open accessAbstract
After years of development and many published studies, prostate-specific membrane antigen–targeted radioligand therapy recently reached a critical milestone on March 23, 2022, with approval of 177Lu-PSMA-617 by the U.S. Food and Drug Administration ([ 1 ][1]). This landmark success heralds a new
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · see citing works
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · see citing works
Self-citationHofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184 · see citing works
Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis.
Leamon, C. P., & Low, P. S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5572 · Cited by 558 · see citing works
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Barrington, S. F., & Kluge, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3690-8 · Cited by 281 · see citing works
Calais, J., & Czernin, J. G. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263159 · Cited by 26 · see citing works
Nuclear medicine theranostics comes of age
Herrmann, K., Krause, B. J., Hadaschik, B. A., Kunikowska, J., van Poppel, H., N'Dow, J. M., Sartor, O., & Oyen, W. J. G. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00540-4 · Cited by 16 · see citing works
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy
Srinivas, S., & Iagaru, A. H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263035 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158 · see citing works
Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., et al. (2024) · Radiology · doi:10.1148/radiol.233460 · Cited by 119 · see citing works
Self-citationKuo, P. H., Yoo, D. C., Avery, R., Seltzer, M., Calais, J., Nagarajah, J., Weber, W. A., Fendler, W. P., Hofman, M. S., Krause, B. J., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265077 · Cited by 22 · see citing works
Self-citation
- Authors
- Kuo, P. H., Benson, T., Messmann, R., & Groaning, M.
- Affiliations
- University of Arizona (US)
- Novartis (Switzerland) (CH)
- Amgen (United States) (US)
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2022-01-27
- Volume
- 63
- Issue
- 6
- Pages
- 816-818
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W4210636357
- Cited by
- 56
- References
- 8
- Citations by year
- 2026: 15 · 2025: 5 · 2024: 13 · 2023: 15 · 2022: 8
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- Journal of Nuclear Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- Endocyte
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- prostate-specific membrane antigen, PSMA PET/CT, 177Lu-PSMA-617, radioligand therapy, VISION trial, patient selection criteria, prostate cancer, PSMA-targeted therapy
- MeSH terms
- Positron Emission Tomography Computed Tomography, Edetic Acid, Gallium Radioisotopes, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
